ArticleBMJ open2023

Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.

Hongye Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.